Strides Pharma Science (Strides) has announced that its wholly-owned subsidiary, Strides Pharma Global, Singapore, has received approval for Potassium Chloride Oral Solution USP, 40 mEq/15mL (20 per cent) from the United States Food & Drug Administration (US FDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Potassium Chloride Oral Solution USP, 40 mEq/15 mL (20 per cent) of Genus Lifesciences Inc.

The approval further strengthens the Potassium Chloride franchise for the company which now consists of extended-release capsules, extended-release tablets, powder for oral solutions and oral solutions. The company also has a pipeline of other potassium chloride products which are expected to be approved and launched in FY24.

The entire potassium chloride range of products for the company has a cumulative market opportunity of ~$330 million as per IQVIA. The products will be manufactured at the company’s facility in Bengaluru and will be marketed by Strides Pharma in the US market.

The company has 280 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with the US FDA of which 261 ANDAs have been approved and 19 are pending approval. The company has set a target to launch ~ 20 new products every year in the US.